Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a  prospective multicenter phase 2 trial

DISCUSSION: As cure rates in localized EBV-positive NPC today are high with standard multimodal treatment, the focus increasingly shifts toward prevention of late effects, the burden of which is exceptionally high, mainly due to intense radiotherapy. Furthermore, survival in patients with metastatic disease and resistant to conventional chemotherapy remains poor. Primary objective of this study is to investigate whether the addition of nivolumab to standard induction chemotherapy in children and adults with EBV-positive NPC is able to increase the rate of complete responses, thus enabling a reduction in radiation dose in more patients, but also offer patients with high risk of treatment failure the chance to benefit from the addition of nivolumab.TRIAL REGISTRATION: EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) No. 2021-006477-32.PMID:38214716 | DOI:10.1007/s00106-023-01404-9

Source: HNO - January 12, 2024 Category: ENT & OMF Authors: Tristan R ömer Christian Vokuhl Gundula Staatz Felix M Mottaghy Hans Christiansen Michael J Eble Beate Timmermann Jens Peter Klussmann Miriam Elbracht Gabriele Calaminus Martin Zimmermann Tim H Br ümmendorf Tobias Feuchtinger Helena Kerp Udo Kontny Source Type: research